GPR18-Mediated Relaxation of Human Isolated Pulmonary Arteries

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163351

Authors

Hanna Kozlowska

Barbara Malinowska

Marta Baranowska-Kuczko

Magdalena Kusaczuk

Milosz Nesterowicz

Miroslaw Kozlowski

Christa E Muller

Katarzyna Kiec-Kononowicz

Eberhard Schlicker

Affiliations

Soon will be listed here.

Abstract

GPR18 receptor protein was detected in the heart and vasculature and appears to play a functional role in the cardiovascular system. We investigated the effects of the new GPR18 agonists PSB-MZ-1415 and PSB-MZ-1440 and the new GPR18 antagonist PSB-CB-27 on isolated human pulmonary arteries (hPAs) and compared their effects with the previously proposed, but unconfirmed, GPR18 ligands NAGly, Abn-CBD (agonists) and O-1918 (antagonist). GPR18 expression in hPAs was shown at the mRNA level. PSB-MZ-1415, PSB-MZ-1440, NAGly and Abn-CBD fully relaxed endothelium-intact hPAs precontracted with the thromboxane A analog U46619. PSB-CB-27 shifted the concentration-response curves (CRCs) of PSB-MZ-1415, PSB-MZ-1440, NAGly and Abn-CBD to the right; O-1918 caused rightward shifts of the CRCs of PSB-MZ-1415 and NAGly. Endothelium removal diminished the potency and the maximum effect of PSB-MZ-1415. The potency of PSB-MZ-1415 or NAGly was reduced in male patients, smokers and patients with hypercholesterolemia. In conclusion, the novel GPR18 agonists, PSB-MZ-1415 and PSB-MZ-1440, relax hPAs and the effect is inhibited by the new GPR18 antagonist PSB-CB-27. GPR18, which appears to exhibit lower activity in hPAs from male, smoking or hypercholesterolemic patients, may become a new target for the treatment of pulmonary arterial hypertension.

Citing Articles

Uncovering the Power of GPR18 Signalling: How RvD2 and Other Ligands Could Have the Potential to Modulate and Resolve Inflammation in Various Health Disorders.

Honkisz-Orzechowska E, Lazewska D, Baran G, Kiec-Kononowicz K Molecules. 2024; 29(6).

PMID: 38542895 PMC: 10976181. DOI: 10.3390/molecules29061258.

Gpr18 agonist dampens inflammation, enhances myogenesis, and restores muscle function in models of Duchenne muscular dystrophy.

Dort J, Orfi Z, Fiscaletti M, Campeau P, Dumont N Front Cell Dev Biol. 2023; 11:1187253.

PMID: 37645248 PMC: 10461444. DOI: 10.3389/fcell.2023.1187253.

Special Issue: "G Protein-Coupled Receptor and Their Kinases in Cell Biology and Disease 2.0".

Cannavo A Int J Mol Sci. 2022; 23(23).

PMID: 36499478 PMC: 9735916. DOI: 10.3390/ijms232315152.

Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling.

Diaz Del Campo L, Rodrigues-Diez R, Salaices M, Briones A, Garcia-Redondo A Int J Mol Sci. 2022; 23(7).

PMID: 35408952 PMC: 8998739. DOI: 10.3390/ijms23073592.

References

Baranowska-Kuczko M, MacLean M, Kozlowska H, Malinowska B . Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. Pharmacol Res. 2012; 66(3):251-9. DOI: 10.1016/j.phrs.2012.05.004. View

Sommer N, Ghofrani H, Pak O, Bonnet S, Provencher S, Sitbon O . Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2020; 178(1):6-30. DOI: 10.1111/bph.15016. View

Baranowska-Kuczko M, Kozlowska H, Kozlowski M, Schlicker E, Kloza M, Surazynski A . Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387(5):477-86. PMC: 3984660. DOI: 10.1007/s00210-014-0961-9. View

Console-Bram L, Brailoiu E, Brailoiu G, Sharir H, Abood M . Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol. 2014; 171(16):3908-17. PMC: 4128052. DOI: 10.1111/bph.12746. View

Kotanska M, Mika K, Szafarz M, Kubacka M, Muller C, Sapa J . Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating. Pharmaceuticals (Basel). 2021; 14(3). PMC: 8002110. DOI: 10.3390/ph14030270. View

Takenouchi R, Inoue K, Kambe Y, Miyata A . N-arachidonoyl glycine induces macrophage apoptosis via GPR18. Biochem Biophys Res Commun. 2012; 418(2):366-71. DOI: 10.1016/j.bbrc.2012.01.027. View

Matouk A, Taye A, El-Moselhy M, Heeba G, Abdel-Rahman A . The Effect of Chronic Activation of the Novel Endocannabinoid Receptor GPR18 on Myocardial Function and Blood Pressure in Conscious Rats. J Cardiovasc Pharmacol. 2016; 69(1):23-33. PMC: 5209303. DOI: 10.1097/FJC.0000000000000438. View

McHugh D, Hu S, Rimmerman N, Juknat A, Vogel Z, Walker J . N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010; 11:44. PMC: 2865488. DOI: 10.1186/1471-2202-11-44. View

Ulu A, Sahoo P, Yuil-Valdes A, Mukherjee M, Van Ormer M, Muthuraj P . Omega-3 Fatty Acid-Derived Resolvin D2 Regulates Human Placental Vascular Smooth Muscle and Extravillous Trophoblast Activities. Int J Mol Sci. 2019; 20(18). PMC: 6770915. DOI: 10.3390/ijms20184402. View

10.

Yoo S, You S, Yoon H, Kim D, Kim H, Lee K . A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis. J Exp Med. 2012; 209(4):871-86. PMC: 3328363. DOI: 10.1084/jem.20111783. View

11.

Finlay D, Joseph W, Grimsey N, Glass M . GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine. PeerJ. 2016; 4:e1835. PMC: 4806671. DOI: 10.7717/peerj.1835. View

12.

McHugh D . GPR18 in microglia: implications for the CNS and endocannabinoid system signalling. Br J Pharmacol. 2012; 167(8):1575-82. PMC: 3525861. DOI: 10.1111/j.1476-5381.2012.02019.x. View

13.

Jarai Z, Wagner J, Varga K, Lake K, Compton D, Martin B . Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A. 1999; 96(24):14136-41. PMC: 24203. DOI: 10.1073/pnas.96.24.14136. View

14.

Macintyre J, Dong A, Straiker A, Zhu J, Howlett S, Bagher A . Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. Eur J Pharmacol. 2014; 735:105-14. DOI: 10.1016/j.ejphar.2014.03.055. View

15.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

16.

Burstein S . Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential. Mol Pharmacol. 2017; 93(3):228-238. DOI: 10.1124/mol.117.110841. View

17.

Kusaczuk M, Kretowski R, Stypulkowska A, Cechowska-Pasko M . Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report. Invest New Drugs. 2016; 34(5):552-64. PMC: 5007275. DOI: 10.1007/s10637-016-0372-5. View

18.

Offertaler L, Mo F, Batkai S, Liu J, Begg M, Razdan R . Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol. 2003; 63(3):699-705. DOI: 10.1124/mol.63.3.699. View

19.

Wang X, Sumida H, Cyster J . GPR18 is required for a normal CD8αα intestinal intraepithelial lymphocyte compartment. J Exp Med. 2014; 211(12):2351-9. PMC: 4235638. DOI: 10.1084/jem.20140646. View

20.

Kozlowska H, Baranowska M, Schlicker E, Kozlowski M, Laudanski J, Malinowska B . Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br J Pharmacol. 2008; 155(7):1034-42. PMC: 2597267. DOI: 10.1038/bjp.2008.371. View